January 8, 2024 in Press Release

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors

Comments Off on HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors HANGZHOU, China--January 8, 2024--HighField Biopha ...

Read More
December 18, 2023 in Press Release

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers

Comments Off on HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers The company’s groundbreaking drug encapsulated imm ...

Read More
October 23, 2023 in Press Release

HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma

Comments Off on HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma

HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma HighField CEO Yuhong Xu and CBO Donald Wyat ...

Read More
Post placeholder image
July 17, 2023 in Press Release

HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma

Comments Off on HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma

HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancerHANGZHOU, CHINA--HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology co ...

Read More
Post placeholder image
June 13, 2023 in Press Release

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

Comments Off on HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

The company’s groundbreaking drug encapsulated immunoliposomes may represent a significant improvement over existing antibody drug conjugatesHANGZHOU, China--June 13, 2023--HighField Biopharmaceutical ...

Read More
Post placeholder image
May 31, 2023 in Press Release

HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma

Comments Off on HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma

The abstract of preliminary data from a Phase 1a trial of HF1K16, which targets myeloid-derived suppressor cells (MDSCs), is published online at the 2023 ASCO Annual Meeting in Chicago, ILHANGZHOU, Ch ...

Read More